The study also revealed that TLR1/2-mediated co-stimulation enhanced antitumor CD8+ T cell function when encountering tumor cells (15), further supporting the potential for leveraging TLR1/2 signaling in immunotherapeutic strategies. The gene discussed is CD8A; the disease is neoplasm.